Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTO NASDAQ:MGTX NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.71$4.41$1.35▼$50.10$3.66M1.04227,964 shsN/AMGTXMeiraGTx$12.44+0.8%$10.76$6.62▼$15.35$1.15B1.2750,645 shs1.28 million shsREPLReplimune Group$9.87-0.7%$8.17$1.50▼$13.24$828.49M0.864.56 million shs3.30 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx-7.84%-11.16%+28.68%+9.30%+45.69%REPLReplimune Group-9.55%-13.34%+11.94%+409.74%-9.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.71$4.41$1.35▼$50.10$3.66M1.04227,964 shsN/AMGTXMeiraGTx$12.44+0.8%$10.76$6.62▼$15.35$1.15B1.2750,645 shs1.28 million shsREPLReplimune Group$9.87-0.7%$8.17$1.50▼$13.24$828.49M0.864.56 million shs3.30 million shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx-7.84%-11.16%+28.68%+9.30%+45.69%REPLReplimune Group-9.55%-13.34%+11.94%+409.74%-9.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 0.00N/AN/AN/AMGTXMeiraGTx 2.75Moderate Buy$26.00109.00% UpsideREPLReplimune Group 2.00Hold$8.13-17.68% DownsideCurrent Analyst Ratings BreakdownLatest APTO, REPL, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$25.00 ➝ $26.007/8/2026MGTXMeiraGTx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/2/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/30/2026REPLReplimune Group BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Outperform$16.006/30/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$6.00 ➝ $9.006/26/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$17.006/18/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$2.00 ➝ $6.005/29/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$8.005/26/2026MGTXMeiraGTx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AMGTXMeiraGTx$81.39M14.15N/AN/A($0.07) per share-177.71REPLReplimune GroupN/AN/AN/AN/A$2.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AMGTXMeiraGTx-$114.20M-$1.48N/AN/AN/A-151.12%N/A-54.96%8/13/2026 (Estimated)REPLReplimune Group-$313.94M-$3.38N/AN/AN/AN/A-128.57%-82.35%8/6/2026 (Estimated)Latest APTO, REPL, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q1 2027REPLReplimune Group-$0.64N/AN/AN/A$13.60 millionN/A6/29/2026Q4 2026REPLReplimune Group-$0.6613-$0.76-$0.0988-$0.76$3.57 millionN/A5/14/2026Q1 2026MGTXMeiraGTx-$0.6060-$0.57+$0.0360-$0.57$17.00 million$0.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05MGTXMeiraGTxN/A0.550.55REPLReplimune Group0.634.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%MGTXMeiraGTx67.48%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%MGTXMeiraGTx7.40%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataMGTXMeiraGTx30092.61 million85.76 millionOptionableREPLReplimune Group21083.94 million79.58 millionOptionableAPTO, REPL, and MGTX HeadlinesRecent News About These CompaniesTraders Purchase Large Volume of Replimune Group Put Options (NASDAQ:REPL)July 13 at 5:59 PM | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Down 6.6% - What's Next?July 13 at 11:59 AM | marketbeat.comReplimune Group, Inc. Common Stock (REPL)July 8, 2026 | nasdaq.comReplimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by AnalystsJuly 5, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Abivax SA Sponsored ADR (ABVX) and Larimar Therapeutics (LRMR)July 1, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR)June 30, 2026 | theglobeandmail.comReplimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be CrucialJune 30, 2026 | seekingalpha.comReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate UpdateJune 29, 2026 | globenewswire.comReplimune’s RP1 BLA Resubmission Accepted for ReviewJune 28, 2026 | theglobeandmail.comReplimune Group Announces FDA Acceptance for Review of RP1 BLA Resubmission in Advanced MelanomaJune 26, 2026 | quiverquant.comQReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced MelanomaJune 26, 2026 | globenewswire.comReplimune: Modeling The Coin Flip Of FDA ApprovalJune 4, 2026 | seekingalpha.comInsider Selling: Replimune Group (NASDAQ:REPL) Insider Sells 12,000 Shares of StockJune 4, 2026 | insidertrades.comReplimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology ...June 1, 2026 | finanznachrichten.deReplimune Group, Inc.: Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical ...June 1, 2026 | finanznachrichten.deWhy Is REPL Stock Gaining In Pre-Market Today?June 1, 2026 | finance.yahoo.comREPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo DrugJune 1, 2026 | zacks.comReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral ...May 31, 2026 | caledonianrecord.comCReplimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026May 31, 2026 | quiverquant.comQReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 31, 2026 | globenewswire.comStock Movers: Dell, Replimune, SnowflakeMay 30, 2026 | bloomberg.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Starbucks Builds Sovereign AI to Cut $400 Million in Software CostsBy Jeffrey Neal Johnson | July 11, 2026APTO, REPL, and MGTX Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.MeiraGTx NASDAQ:MGTX$12.44 +0.10 (+0.81%) Closing price 04:00 PM EasternExtended Trading$12.42 -0.01 (-0.12%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Replimune Group NASDAQ:REPL$9.87 -0.07 (-0.70%) Closing price 04:00 PM EasternExtended Trading$9.74 -0.13 (-1.32%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
